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OBJECTIVE: The objective of this study was to docu-
ment the clinical and economic characteristics of ambula-
tory family medicine patients receiving antidepressant
medications.
METHODS: The medication profiles of the electronic
medical records (EMR) of all Family Medicine patients at
the Medical College of Georgia were evaluated. Only pa-
tients prescribed an antidepressant drug within the previ-
ous 6 months were reviewed. Patient records were re-
viewed in the order in which they were entered into the
EMR system.
RESULTS: The electronic records of 116 patients were
reviewed by the same physician researcher. Demographic
and clinical data for 89 (76.7%) female and 27 (23.3%)
male patients were evaluated. The mean age for these pa-
tients was 46.5 years. Sixty-two (53.4%) patients were
white, 38 (32.8%) were black. Although usually consid-
ered risk factors for the development of depression, mari-
tal status and the use of alcohol were not noted in 47
(40.5%) and 62 (53.4%) patients, respectively. The most
common comorbid conditions were hypertension (47.4%),
gastroesophageal reflux disease (GERD) (20.7%), arthritis
(20.7%), anxiety (18.1%), diabetes mellitus (17.2%), and
pain syndromes (45.7%). Thirty-one (26.7%) patients, re-
ceived amitriptyline. Twenty-two (71%) received less than
50 mg per day. Fourteen (12%) patients received two an-
tidepressants, most often an SSRI in the morning with a
sedating agent at bedtime. Of the 26 patients with avail-
able financial data, 25 patients paid a co-payment of $5.00
or less. 
CONCLUSIONS: Antidepressant drugs are frequently
prescribed in primary care patients with multiple comor-
bid conditions (mean 3.9).
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OBJECTIVE: The objective of this study was to examine
the cost-effectiveness of fluvoxamine compared to treat-
ment with tricyclic antidepressants (TCAs) in patients
who suffer depressive episodes.
METHODS: The setting for this study was France. A
Markov process model was constructed to model the ef-
fectiveness, as measured by time without depression, and
the costs of both treatments. The model examined a pe-
riod of 18 months in order to capture the influence of
both relapses and recurrences on the outcomes. Data for
the construction of the model came from the published
literature, an expert panel, and a large multicenter ran-
domized clinical trial. Costs were obtained from pub-
lished sources.
RESULTS: The results of the baseline analysis showed
that the use of fluvoxamine in the maintenance treatment
(recurrence prevention) of depressive disorders was less
costly than TCAs with total costs (direct and indirect
costs) of 40,232.40 FF versus 52,257.53 FF, respectively.
In addition, due to the prevention of relapse and recur-
rence, effectiveness fluvoxamine was favored, as it was
associated with a longer period of time without depres-
sion when compared to therapy with TCAs: 79% of the
study period compared to 71% for TCAs. Sensitivity
analyses confirmed the robustness of these findings.
CONCLUSION: In conclusion, based on the assump-
tions used in the model, the use of fluovoxamine as main-
tenance therapy is clinically and economically justified in
patients with depressive disorders.
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OBJECTIVE: We conducted a multinational pharmaco-
economic evaluation of treatment for major depressive
disorder (MDD) to assess the potential budget impact of
changes in antidepressant prescribing patterns in Canada,
Germany, Italy, the Netherlands, Poland, Spain, Sweden,
Switzerland, the United Kingdom, the United States, and
Venezuela. 
METHODS: The analysis compared the serotonin-nore-
pinephrine reuptake-inhibitor (SNRI), extended-release
venlafaxine, to selective serotonin reuptake-inhibitors
(SSRIs) and tricyclic antidepressants (TCAs). A meta-
analysis was performed to determine the clinical rates of
success, defined as a 50% reduction in depression scores
on the Hamilton Depression Scale (HAM-D) or the
Montgomery-Asberg Depression Rating Scale (MADRS).
Treatment regimen costs were determined from standard
lists, fee schedules, and communication with local health
economists in each country. We included data from 48
studies on 4,690 patients in the meta-analysis. The meta-
analytic rates were applied to decision analytic models to
calculate expected cost and expected outcomes for each
comparator. Cost-effectiveness was determined using ex-
pected values for both a successful outcome (as defined
by the meta-analysis), and a composite measure of out-
come termed “Symptom-Free Days.” A policy analysis
was conducted to examine the budgetary impact on the
health system, in each country, of increasing the utiliza-
tion of the most effective comparator.
RESULTS: Treatment of MDD with extended-release
venlafaxine yielded the highest overall efficacy rates for
outpatients (73.7%) and inpatients (62.3%). Extended-
release venlafaxine had the highest failure rate due to lack
of efficacy (5.3%) and adverse drug reactions (11.3%).
Initiating treatment of MDD with extended-release ven-
lafaxine yielded the lowest expected cost for outpatients
